Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 4 November 2026.
Announcements
6,263
Total raised
£165B
disclosed amounts
This month
£177M
raised so far
Joint Journey led the pre-seed round, with backing from PLF and individual investors, to fund product development and international growth.
"It’s immensely encouraging to have customers knocking at the door so early in DigiDoe’s journey, as we revolutionise the creaky payments infrastructure that businesses have to deal with every day."
The University of Sheffield spin-out raised a seven-figure sum from a syndicate to develop quantum-secure networking.
"The single photon source developed by Aegiq represents a platform technology with unparalleled specifications that enables various applications. As a photonics guy, I am more than thrilled to invest here and support the highly skilled team on their journey,"
The funding round was provided entirely by existing investors Augmentum Fintech and AshGrove Capital to support the acquisition of the Creative auto-enrolment scheme and scale operational capability.
"Our mission is to offer UK savers a convenient, climate-friendly, and great value way to save, through a combination of cutting-edge technology and socially responsible investments. Right now, workplace pensions are simply too complicated, boring, and disconnected from things people care deeply about. Cushon is here to change that, and today’s announcement is a hugely significant milestone for us. The funding will continue to fuel Cushon’s growth, enable us to scale even faster, and accelerate some exciting new features within our app."
The financing round was co-led by Netherton Investments and Dompé farmaceutici.
"Our mission is to improve people’s lives and we partner with the best academic and industrial groups to accelerate the research that will bring new solutions to patients’ unmet needs. We look forward to working with the Engitix team to combine the power of Exscalate with Engitix’s deep understanding of the biology of the fibrosis and solid tumours microenvironment and the unique strength of its ECM platform. Our collaboration will enable us to accelerate the clinical translation of targets beyond our four key in-house therapeutic areas of ophthalmology, metabolic disorders, oncology, and pain management."
The investment was led by BGF and Parkwalk to support pre-clinical work, clinical trials, and regulatory approval.
"There are over three million dialysis patients worldwide and every year patients undergo nearly 650,000 surgical AVF creation procedures. However, these procedures take a long time to heal and are prone to failure. Our technology has the power to significantly improve the outcomes for dialysis patients, improving their quality of life and saving millions of pounds in the process. We are delighted to have the support of BGF and Parkwalk to help the business move forward with our clinical trials and ultimately roll-out this ground-breaking product to a global market."
